EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

TP53 Mutations in Esophageal Squamous Cell Carcinoma

Leqi Zhong, Hongmu Li, Wuguang Chang, Yong Ao, Zhesheng Wen, Youfang Chen

Frontiers in Bioscience-Landmark · 24.09.2023 · 28 (9)

DOI: 10.31083/j.fbl2809219 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 24.09.2023. Verfasst von Leqi Zhong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Sun Yat-Sen University Cancer Center, 510060 Gunagzhou, Guangdong, China. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The occurrence and development of esophageal cancer involve multiple genetic abnormalities that contribute to the malignant transformation of esophageal epithelial cells, followed by invasion and metastasis, leading to a poor outcome. Esophageal squamous cell carcinoma (ESCC) is the predominant histological subtype of esophageal malignancy in East Asia, with approximately half of newly diagnosed ESCC cases occurring in China. The TP53 tumor suppressor gene mutation is one of the most common mutations in ESCC. TP53 mutations are observed even in the early phases of esophageal carcinogenesis. Normal functions of the p53 network are lost in cells of ESCC patients who harbor the mutant TP53 gene, inducing tumor development, radiation resistance, chemotherapy resistance, and immune suppression, promoting progression and metastasis, thereby resulting in an overall poor prognosis. Although clinical trials of several pharmacological compounds targeting mutational TP53 have been explored, novel approaches are still urgently required to improve the observed dismal survival. A better understanding of the role of the mutant TP53 gene in human ESCC might lead to the discovery of innovative targeted therapies to treat this malignancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal Squamous Cell CarcinomaEsophageal NeoplasmsHumansTumor Suppressor Protein p53MutationChina

Stichwörter der Autor:innen

TP53 mutationsesophageal squamous cell carcinomatargeted therapies

Substanzen

Tumor Suppressor Protein p53TP53 protein, human

Autor:innen und Institutionen

  • Department of Thoracic Oncology, Sun Yat-Sen University Cancer Center, 510060 Gunagzhou, Guangdong, China.
  • Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 510060 Guangzhou, Guangdong, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhong, L., Li, H., Chang, W., Ao, Y., Wen, Z., & Chen, Y. (2023). TP53 Mutations in Esophageal Squamous Cell Carcinoma. Frontiers in Bioscience-Landmark, 28(9). https://doi.org/10.31083/j.fbl2809219

Vancouver

Zhong L, Li H, Chang W, Ao Y, Wen Z, Chen Y. TP53 Mutations in Esophageal Squamous Cell Carcinoma. Frontiers in Bioscience-Landmark. 2023;28(9). doi:10.31083/j.fbl2809219

BibTeX
@article{Zhong2023,
  author = {Zhong, Leqi and Li, Hongmu and Chang, Wuguang and Ao, Yong and Wen, Zhesheng and Chen, Youfang},
  title = {TP53 Mutations in Esophageal Squamous Cell Carcinoma},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2023},
  volume = {28},
  number = {9},
  doi = {10.31083/j.fbl2809219}
}
Kostenlos starten →